Apac
  • Home
  • CXO Insights
  • CIO Speaks
  • Partner Conferences
  • Newsletter
  • Subscribe
  • News
  • About us
Apac
  • Agile

    Artificial Intelligence

    Augmented Reality

    Big Data

    Blockchain

    Cloud

    Cyber Security

    DevOps

    Digital Technology

    Enterprise Security

    HPC

    Internet of Things

    IT Services

    Mobility

    Networking

    Open Source

    POS

    QA and Testing

    Robotics

    SaaS Solutions

    Security

    Simulation

    Smart City

    Startup

    Storage

    Unified Communication

    Virtualization

    Web Development

    Wireless

  • Automotive

    Aviation and Aerospace

    Banking

    Compliance

    Construction

    Contact Center

    E-Commerce

    Education

    Energy

    Engineering

    Field Service

    FinTech

    Gov and Public

    Healthcare

    Insurance

    Legal

    Logistics

    Manufacturing

    Media and Entertainment

    Metals and Mining

    Pharma and Life Science

    Retail

    Sports

    Telecom

    Travel and Hospitality

    Utilities

  • Amazon

    CISCO

    Dynamics 365

    Google

    HP

    IBM

    Intel

    Microsoft

    Microsoft Azure

    Oracle

    Red Hat

    Salesforce

    SAP

    Share Point

    VMware

  • Business Intelligence

    Business Process Management

    CEM

    Cognitive

    Collaboration

    Corporate Finance

    CRM

    Data Center

    Disaster Recovery

    Document Management Systems

    Enterprise Architecture

    Enterprise Asset Management

    Enterprise Performance Management

    ERP

    Fleet Management

    Gamification

    Geographical Information System

    HR Technology

    IT Service Management

    Managed Services

    Payments

    PLM

    Procurement

    Project Management

    Risk Management

    Sales and Marketing

    Workflow

Menu
    • Amazon
    • Banking
    • Blockchain
    • CISCO
    • Cognitive
    • Compliance
    • Contact Center
    • Cyber Security
    • DevOps
    • E-Commerce
    • Field Service
    • Gov and Public
    • Healthcare
    • HR Technology
    • IoT
    • Managed Services
    • Manufacturing
    • Metals and Mining
    • Microsoft
    • Oracle
    • Pharma and Life Science
    • Retail
    More
    DevOps E-Commerce Field Service Gov and Public Healthcare HR Technology IoT Managed Services Manufacturing Metals and Mining Microsoft Oracle Pharma and Life Science Retail
    ×

    Subscribe to our Newsletter

    news
    news

    Join our mailing list for the latest articles, news, and exclusive insights from prominent technology leaders

    loading
    SUBSCRIBE

    Thank You for subscribing with us. We sent you an email regarding this.

    news

    • Home
    • News
    • Pharma and Life Science
    Editor's Pick (1 - 4 of 8)
    left
    Cloud Computing: Pharma Takes the Plunge

    Andy Newsom, SVP & CIO, CSL Behring

    Machine Learning & Artificial Intelligence in Healthcare Industry

    James Woo, CIO, The Farrer Park Company

    Connected Patients: Healthcare and the Internet of Things

    Geoff Feakes, Group CIO, Tunstall Healthcare Group

    Healthcare IT solution Delivery and the Cloud

    Arvind N Sivaramakrishnan, CIO, Apollo Hospitals

    Building a Quality-Focused IT Foundation for a Biopharmaceutical Enterprise

    Andy Newsom, SVP, CIO, CSL Behring

    Points of Focus for CIOs to Succeed in the Next Decade and Beyond

    Dr. Joseph Frassica, CMIO/CTO, Patient Care and Monitoring Solutions, Philips Healthcare

    Innovating Technology -Based Metadata Solutions for Improved Data Analysis

    Douglas Barta, CIO, PAREXEL International

    Real-Time Actionable Intelligence with a Solid Analytics Platform

    Rajeev Nair,

    right

    Use of Hydroxyurea in Combination Chemotherapy may Improve Treatment of Brain Tumor

    By Apac Ciooutlook | Monday, December 03, 2018
    Tweet

    Hydroxyurea has recently been found to improve chemotherapy effectiveness in the treatment of brain tumor. Massachusetts General Hospital’s (MGH) research team published their findings in the Neuro-Oncology journal that the addition of hydroxyurea, a medication drug to the current chemotherapy treatment for glioblastoma drastically raised the number of survivals in animal subjects. The findings of the research published in recently.  

    According to the findings, hydroxyurea, an FDA-approved drug works and cooperates with another drug, temozolomide (TMZ) to act on glioblastoma cells. The combination of two drugs proved to be more effective than the individual application of either on glioblastoma samples of newly diagnosed and recurrent tumors, even in cases where they were resistant to chemotherapy. The new discovery helped to increase the survival rate of different mouse models, and around 40 to 60 percent of the mice became tumor-free in some of the cases.

    The use of TMZ in addition to surgical and radiation treatment has been a milestone in glioblastoma treatment in the past two decades, raising two years of survival from 11 percent to 27 percent. However, 90 percent of the patients who obtain this combination of treatment still lose their lives within five years due to the intensification of resistance to TMZ, which works by inhibiting the synthesis of proteins within cancer cells. 

    The MGH-led team, in its search for the ways to defeat resistance to TMZ, experimented with 21 drugs that were existing in the market and approved already for curing several types of cancers. Out of these drugs, only hydroxyurea worked on all cell lines including many which were earlier resistant to TMZ treatment.

    Around 50 percent of the mice that obtained the new combination treatment remained tumor-free at the end of the study period. Also, among those with a precise subtype of tumor, 60 percent animals were found cured.  The team of researchers is on their way to test the new drug combination in phase 1 clinical trials, shortly.

    Read Also

    Redefining Healthcare with Personalized Medicine

    Redefining Healthcare with Personalized Medicine

    University of Bern and the Netherlands Cancer Institute Use 3D Cell Cultures to Study about Cancer Therapy Resistance

    University of Bern and the Netherlands Cancer Institute Use 3D Cell Cultures to Study about Cancer Therapy Resistance

    Individualizing Drug doses Amongst Patients of Depression

    Individualizing Drug doses Amongst Patients of Depression

    Singapore Drives Pharmaceutical and Therapeutic Innovation

    Singapore Drives Pharmaceutical and Therapeutic Innovation

    Featured Vendors

    SalesFix

    Jason Lawrence, CEO

    Bentley Systems

    Greg Bentley , CEO

    New Editions

    Copyright © 2019 APAC CIOoutlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy Policy  |  Sitemap

    follow on linkedinfollow on twitter follow on rss
    This content is copyright protected

    However, if you would like to share the information in this article, you may use the link below:

    https://www.apacciooutlook.com/news/use-of-hydroxyurea-in-combination-chemotherapy-may-improve-treatment-of-brain-tumor-nwid-4896.html